Company profile for Philogen

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, with the mission to develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders. Angiogenesis, i.e. the formation of new blood vessels, is a characteristic feature of many severe pathologies such as cancer, rheumatoid arthritis and age-related macular degeneration. The company has been a pioneer in the isolation, enginee...
Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, with the mission to develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders. Angiogenesis, i.e. the formation of new blood vessels, is a characteristic feature of many severe pathologies such as cancer, rheumatoid arthritis and age-related macular degeneration. The company has been a pioneer in the isolation, engineering and clinical development of lead products capable of targeting angiogenesis in-vivo and has been the first in the world to demonstrate that human monoclonal antibodies, specific for a marker of angiogenesis,etc.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Italy
Address
Address
Via Bellaria, 35, 53018 Sovicille (SI)
Telephone
Telephone
(+39) 0577.1781.6
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.indianpharmapost.com/clinical-trials/philogen-updates-on-fibromun-clinical-study-developments-18225

INDPHARMAPOST
13 Nov 2025

https://www.indianpharmapost.com/news/philogen-withdraws-marketing-authorization-application-for-nidlegy-in-eu-17312

INDPHARMAPOST
26 Jun 2025
Sun Pharma, Philogen Enter Exclusive Licensing Pact For Firbomun
Sun Pharma, Philogen Enter Exclusive Licensing Pact For Firbomun

30 Sep 2024

// Viswanath Pilla ECONOMICTIMES

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-philogen-enter-exclusive-licensing-pact-for-commercialisation-of-specialty-cancer-drug-firbomun/articleshow/113838280.cms

Viswanath Pilla ECONOMICTIMES
30 Sep 2024

https://www.pharmabiz.com/NewsDetails.aspx?aid=170120&sid=2

PHARMABIZ
04 Jul 2024

https://www.pharmaceutical-technology.com/news/sun-pharma-philogen-melanoma-therapy/

PHARMACEUTICAL TECHNOLOGY
04 Jun 2024

https://www.globenewswire.com//news-release/2024/02/20/2831505/0/en/Philogen-provides-update-on-pre-planned-interim-analysis-of-the-Phase-III-FIBROSARC-trial-investigating-Onfekafusp-alfa-L19TNF-in-patients-with-first-line-advanced-or-metastatic-So.html

GLOBENEWSWIRE
20 Feb 2024

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty